

OREGON HEALTH POLICY AND RESEARCH

Health Resources Commission

Issue 16, updated 8-05

OREGON HEALTH POLICY AND RESEARCH

Health Resources Commission

Issue 18, updated 3-06

Oregon's Drug Review:

Targeted Immune Modulators (TIM)

These drugs are used in the treatment of certain types of immunologic and inflammatory diseases including rheumatoid arthritis (RA), juvenile rheumatoid arthritis(JRA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and Crohn's disease of the bowel.

Which Drugs Were Included In This Review?

This review looked at the following TIM drugs:

Biological Response Modifiers: <u>Anti-TNF Drugs</u> <ul style="list-style-type: none">• Adalimumab (Humira®)• Etanercept (Enbrel®)• Infliximab (Remicade®)	<u>Anti Interleukin-1</u> Anakinra (Kineret®)
--	---

What Do These Drugs Treat?

- In patients with RA; adalimumab, etanercept or infliximab are similarly effective and superior to anakinra as compared to placebo.
- In patients with JRA only etanercept has shown evidence for effectiveness.
- In patients with AS and PSA both etanercept and infliximab are more effective than placebo.
- In patients with Crohn's only infliximab has proven efficacious.

What Don't These Drugs Treat?

- In patients with Crohn's disease, etanercept did not show efficacy.

Ask The Patient's Health Care Practitioner During Their Next Visit:

- Is the patient taking the most effective drug for their condition?
 - Are there alternative drugs available that are equally effective?
 - Are there alternatives drugs available that are effective, but less costly?
 - Is there a generic available for the brand name drug?
 - Will this drug interact with other medications the patient takes?
-

Evidence-Based Drug Reviews are available at <http://www.oregonrx.org>

Click on Oregon's Research. Click on Evidenced-Based Reports. Click on desired One Page Consumer Report.

Evidence-Based Drug Reviews are available at <http://www.oregonrx.org>

Click on Oregon's Research. Click on Evidenced-Based Reports. Click on desired One Page Consumer Report.